We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of a Probiotic on Seasonal Allergic Rhinitis Symptoms

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01653652
First Posted: July 31, 2012
Last Update Posted: November 20, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Nestlé
  Purpose
The purpose of the current study is to evaluate the efficacy of administering a probiotic in adult human subjects suffering from allergic rhinitis during seasonal grass pollen exposure.

Condition Intervention
Seasonal Allergic Rhinitis Dietary Supplement: Probiotic Dietary Supplement: Maltodextrin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Mitigation of Seasonal Allergic Rhinitis Symptoms in Adults by Probiotic Intervention

Resource links provided by NLM:


Further study details as provided by Nestlé:

Primary Outcome Measures:
  • Total nasal symptom score (TNSS) [ Time Frame: every day over 8 weeks ]
    Total nasal symptom score (TNSS) measuring nasal congestion, runny nose, nasal itching and sneezing on a scale of 0-12 will be compared over 8 weeks between the two treatment groups.


Secondary Outcome Measures:
  • Total ocular symptom score (TOSS) [ Time Frame: every day over 8 weeks ]
  • miniRQLQ [ Time Frame: every week for 8 weeks ]
    Validated rhinoconjunctivitis quality of life questionnaire (mini RQLQ) measured weekly

  • Individual nasal and ocular symptoms scores [ Time Frame: every day over 8 weeks ]
  • Well being index [ Time Frame: every week over 8 weeks ]
  • Medication Score [ Time Frame: every week over 8 weeks ]
  • Specific IgE [ Time Frame: Baseline and end of study ]

Enrollment: 131
Study Start Date: April 2012
Study Completion Date: December 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
maltodextrin powder to be taken daily
Dietary Supplement: Maltodextrin
Active Comparator: Probiotic
Probiotic blended in maltodextrin powder to be taken daily
Dietary Supplement: Probiotic

Detailed Description:
Adult subjects with documented seasonal allergic rhinitis (SAR) to grass pollen will be assigned to placebo or probiotic groups and take either placebo or probiotic dietary intervention for 8 weeks during the grass pollen allergy season. Total nasal symptom score (TNSS) will be compared over 8 weeks between the two treatment groups.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults aged 18 to 65 years of age at the time of enrolment.
  • Established seasonal allergic rhinitis (clinical history of rhinorrhea, congestion, sneezing, pruritis >2 years)
  • Positive Skin Prick Test (SPT)to Grass Pollen (GP).
  • Presence of specific IgE to Grass Pollen (GP)
  • Have a Body Mass Index in the range 19-32 kg/m2
  • Have signed the consent form
  • Have been instructed during screening and agreed to not take any probiotic containing products outside the study for the study period

Exclusion Criteria:

  • Subjects currently under treatment with antibiotics or undergoing allergen immunotherapy at the time of enrolment
  • Pregnancy
  • Vasomotor rhinitis, nasal cavity disorders (nasal polyps), ear infections otitis media).
  • Other chronic diseases (e.g. gastrointestinal, cardiovascular, infections)
  • Subjects diagnosed with asthma
  • Subjects currently participating in another interventional clinical trial or having participated in another clinical trial in the last 2 months
  • Subjects on chronic use of systemic corticosteroids prior to randomization
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01653652


Locations
Germany
Charité Research Organisation GmbH
Berlin, Germany
Sponsors and Collaborators
Nestlé
  More Information

Responsible Party: Nestlé
ClinicalTrials.gov Identifier: NCT01653652     History of Changes
Other Study ID Numbers: 11.31. NRC
First Submitted: July 27, 2012
First Posted: July 31, 2012
Last Update Posted: November 20, 2013
Last Verified: November 2013

Keywords provided by Nestlé:
grass pollen
allergic rhinitis
TNSS
miniRQLQ

Additional relevant MeSH terms:
Rhinitis
Rhinitis, Allergic
Rhinitis, Allergic, Seasonal
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases